HSP90AA1 and ovarian carcinoma: To investigate whether the HSP90AB1/IGF1R axis is the pathway through which ME ameliorates cisplatin resistance in ovarian cancer cells, we pretreated cells with geldanamycin to inhibit HSP90 ATPase activity prior to treatment with cisplatin and ME.